Idera Pharmaceuticals to Present at the 17th Annual NewsMakers in the Biotech Industry Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 2:30 p.m. ET at the Millennium Broadway Hotel & Conference Center in New York City.

The live audio webcast presentation will be available in the Investor section of the company’s website at www.iderapharma.com. Archived replays will also be available on the company’s site for two weeks following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The company’s proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Idera’s pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.



CONTACT:

Idera Pharmaceuticals, Inc.
Teri Dahlman, 617-679-5519
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.